Press release from Companies
Published: 2014-12-08 09:30:21
WntResearch AB today announces that the European Patent Office (EPO) has informed the company that the EPO intends to grant European patent No. EP 2 384 763 relating to fifteen formylated peptides, including the company's product Foxy-5, and also to pharmaceuticals composition comprising such peptides and use thereof in the treatment of cancer. EPO's communication means that the patent likely will be issued during the first half of 2015; however before grant of the patent, further actions must be taken both by the company and the EPO. Patents covering i.a. Foxy-5 have earlier been issued in Australia, China, Japan and the United States.
VD Nils Brünner comments: “We are very pleased that our patent portfolio is building up to be very strong and a valuable asset for the company.” For additional information please contact: Nils Brünner, VD E-mail: nbr@wntresearch.com Telephone: + 45 2614 4708 About WntResearch WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer. WntResearch has one drug candidate in clinical phase I – Foxy-5 – as well as one candidate drug in preclinical development – Box-5. The Company is currently focusing mainly on the development of Foxy-5.
